Maravai LifeSciences Holdings, Inc. (MRVI) is a Biotechnology company in the Healthcare sector, currently trading at $3.28. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is MRVI = $5 (+37.2% upside).
Valuation: MRVI trades at a trailing Price-to-Earnings (P/E) of -3.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.18.
Financials: revenue is $186M, -35.3%/yr average growth. Net income is $131M (loss), growing at -45.4%/yr. Net profit margin is -70.4% (negative). Gross margin is 18% (-62.9 pp trend).
Balance sheet: total debt is $36M against $212M equity (Debt-to-Equity (D/E) ratio 0.17, conservative). Current ratio is 6.6 (strong liquidity). Debt-to-assets is 4.6%. Total assets: $771M.
Analyst outlook: 7 / 14 analysts rate MRVI as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 97/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 67/100 (Partial), Moat 21/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).
